BCRX NASDAQ
BioCryst Pharmaceuticals, Inc.
1W: +2.0%
1M: -4.4%
3M: -15.0%
YTD: +8.0%
1Y: +12.5%
3Y: +37.8%
5Y: -46.1%
$8.10
+0.22 (+2.79%)
Weekly Expected Move ±5.3%
$7
$7
$8
$8
$8
Credit Risk of going bust: lower than 54% of companies Debt: 16.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.15 (down 98%), BioCryst Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $409.9M against a stock market value of $2.07B.
Distance to default 5.48 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $197.7M (short-term plus half of long-term), stock volatility 47.5%; Altman Z'' -13.51. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.15 (down 98%), BioCryst Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $409.9M against a stock market value of $2.07B.
Distance to default 5.48 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $197.7M (short-term plus half of long-term), stock volatility 47.5%; Altman Z'' -13.51. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
BioCryst wins FDA nod for Orladeyo oral pellets
BioCryst Pharmaceuticals, Inc. (BCRX) – What Are Brokerages Saying About This Stock?
4 Biotech Stocks to Watch as Potential Takeover Targets
Undervalued healthcare stocks with attractive valuation grades
PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
Ten healthcare stocks with A-rated valuations and strong revenue growth
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation - Stocktwits
Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
BioCryst to Present at Upcoming Investor Conference
Morgan Stanley's healthcare conference is set to feature BioCryst on Sept. 15. - stocktitan.net
Canada Pension Plan Investment Board Buys Shares of 115,805 BioCryst Pharmaceuticals, Inc. $BCRX
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?
Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
BCRX Should I Buy - Intellectia AI
BioCryst’s Orladeyo Built The Cash Pile, CEO Gayer Wants To Buy The Next Asset
Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet
Wall Street Analysts Think BioCryst (BCRX) Could Surge 108.21%: Read This Before Placing a Bet
ADAR1 Capital Management LLC Takes $1.33 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Rating of “Moderate Buy” from Brokerages
What is HC Wainwright’s Forecast for BCRX Q3 Earnings?
Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update?
Bank of America Corp DE Buys 3,556,208 Shares of BioCryst Pharmaceuticals, Inc. $BCRX
BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain
Assenagon Asset Management S.A. Buys 120,097 Shares of BioCryst Pharmaceuticals, Inc. $BCRX
BioCryst Pharmaceuticals (BCRX) Stock Looks Cheap Even After A 53% Gain - Yahoo Finance
Why Did BioCryst Pharmaceuticals (BCRX) Shares Climb After Its Latest Update? - Yahoo Finance
BioCryst (BCRX) Q2 2026 Earnings Call Transcript
BioCryst (BCRX) Q2 2026 Earnings Call Transcript
Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?
Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High? - Yahoo Finance
Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options
Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options
BioCryst Pharmaceuticals Inc (BCRX) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
BioCryst Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
BioCryst Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
BioCryst Bets On Rare Genetic Disorder Therapy Expansion Amid Q2 Earnings Beat – Retail Piles On Buyout Speculation
BioCryst Pharmaceuticals Q2 Earnings Call Highlights
BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates
BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates
BioCryst Reports Second Quarter 2026 Financial Results
BioCryst Pharmaceuticals (BCRX) Stock Stalls Despite Profit Surge And ORLADEYO Strength - simplywall.st
Here are the major earnings before the open Wednesday
ADAR1 Capital Management LLC Has $1 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX
BioCryst (BCRX) Stock Looks Like A Bargain After Facility Closure - simplywall.st
Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet
Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet - Yahoo Finance
BioCryst (BCRX) Stock Looks Below Fair Value As Caution Lingers - Yahoo Finance
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains? - Yahoo Finance
Ono Pharmaceutical Co. (OPHLF) Moves 10.4% Higher: Will This Strength Last?
BioCryst lures 9 new hires with stock awards tied to $9.65 shares - stocktitan.net
BCRX Stock Set For Best Week In Over 3 Months – Retail Shifts Focus To This Crucial Breakout Level - Yahoo Finance
Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?
Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now? - Yahoo Finance
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings
Earnings Scheduled For May 6, 2026
BioCryst (BCRX) Q1 2026 Earnings Transcript
BioCryst Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
BioCryst maintains $625M-$645M 2026 ORLADEYO revenue outlook while signing $70M upfront navenibart Europe license
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates
Full Transcript: BioCryst Pharma Q1 2026 Earnings Call
BioCryst Pharmaceuticals GAAP EPS of -$2.98 misses by $3.03, revenue of $156.4M beats by $5.28M
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
Here are the major earnings before the open Wednesday
Is It Time To Reassess BioCryst Pharmaceuticals (BCRX) After Its Recent Share Price Gains - Yahoo Finance
BioCryst to Present at Upcoming Investor Conferences
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Bayforest Capital Ltd
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of “Moderate Buy” by Analysts
Aberdeen Group plc Buys Shares of 913,593 BioCryst Pharmaceuticals, Inc. $BCRX
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
Investors Buy Large Volume of BioCryst Pharmaceuticals Call Options (NASDAQ:BCRX)
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Insider Selling: BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $1,372,500.00 in Stock
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now? - Yahoo Finance
BioCryst gains amid takeover speculation
BioCryst (BCRX) Soars 13% on Acquisition Buzz - Yahoo Finance
Alkeon Capital Management LLC Trims Position in BioCryst Pharmaceuticals, Inc. $BCRX
Avoro Capital Advisors LLC Trims Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Fisher Asset Management LLC
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 10.7% After Better-Than-Expected Earnings
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript
BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
Here are the major earnings before the open Thursday
BioCryst Pharmaceuticals Q4 2025 Earnings Preview
BioCryst to Present at Upcoming Investor Conference
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of “Moderate Buy” from Analysts
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema
Analyzing BioCryst Pharmaceuticals (NASDAQ:BCRX) and Prelude Therapeutics (NASDAQ:PRLD)